Credit Agricole S A Sells 25,640 Shares of Intuitive Surgical, Inc. $ISRG

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Credit Agricole S A reduced its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 12.9% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 172,405 shares of the medical equipment provider's stock after selling 25,640 shares during the quarter. Credit Agricole S A's holdings in Intuitive Surgical were worth $85,387,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. AlphaCore Capital LLC grew its position in Intuitive Surgical by 4.2% during the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock valued at $235,000 after purchasing an additional 18 shares in the last quarter. Second Line Capital LLC grew its position in Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock valued at $302,000 after purchasing an additional 19 shares in the last quarter. Colonial Trust Co SC grew its position in Intuitive Surgical by 8.8% during the fourth quarter. Colonial Trust Co SC now owns 246 shares of the medical equipment provider's stock valued at $128,000 after purchasing an additional 20 shares in the last quarter. Crown Wealth Group LLC grew its position in Intuitive Surgical by 4.8% during the first quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock valued at $218,000 after purchasing an additional 20 shares in the last quarter. Finally, FSM Wealth Advisors LLC grew its position in Intuitive Surgical by 3.8% during the first quarter. FSM Wealth Advisors LLC now owns 546 shares of the medical equipment provider's stock valued at $270,000 after purchasing an additional 20 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Insider Transactions at Intuitive Surgical

In other news, SVP Mark Brosius sold 216 shares of the business's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the sale, the senior vice president directly owned 907 shares in the company, valued at approximately $510,740.77. The trade was a 19.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Myriam Curet sold 4,500 shares of the business's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the transaction, the executive vice president directly owned 353 shares in the company, valued at $173,845.44. This trade represents a 92.73% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 15,839 shares of company stock worth $7,896,972. 0.70% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on ISRG shares. Piper Sandler reiterated an "overweight" rating and issued a $595.00 target price (up from $575.00) on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Erste Group Bank reiterated a "hold" rating on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft cut shares of Intuitive Surgical from a "hold" rating to a "sell" rating and reduced their target price for the company from $515.00 to $440.00 in a research note on Monday, June 9th. Evercore ISI lifted their target price on shares of Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Finally, Wall Street Zen upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Thirteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Intuitive Surgical has a consensus rating of "Moderate Buy" and an average price target of $595.95.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock traded up $6.28 on Friday, reaching $476.16. The stock had a trading volume of 2,023,902 shares, compared to its average volume of 1,973,062. The business's 50-day moving average price is $504.42 and its two-hundred day moving average price is $521.58. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $616.00. The stock has a market cap of $170.69 billion, a P/E ratio of 66.41, a price-to-earnings-growth ratio of 4.99 and a beta of 1.59.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. During the same period in the previous year, the company earned $1.78 earnings per share. Intuitive Surgical's revenue for the quarter was up 21.4% on a year-over-year basis. As a group, equities analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.